Posted by Michael Wonder on 15 Nov 2020
Insmed receives Priority Medicines (PRIME) designation from EMA for brensocatib in patients with non-cystic fibrosis bronchiectasis
13 November 2020 - Insmed today announced that the EMA has granted Priority Medicines (PRIME) designation to brensocatib for the treatment of non-cystic fibrosis bronchiectasis.
Brensocatib is a novel, first-in-class, oral, reversible inhibitor of dipeptidyl peptidase 1 being developed by Insmed for the treatment of patients with non-cystic fibrosis bronchiectasis and other inflammatory diseases.
